Composite outcomes in renal transplantation using cyclosporine

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S35-S39

  Keown, P A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ECONOMIC ASPECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 1642269965     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.060     Document Type: Article

References (41)

1. U.S. Renal Data System: Annual Data Report: Atlas of end-stage renal disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.
2. Van Dijk P: Renal replacement therapy in Europe. The results of a collaborative effort by the ERA-EDTA and six national or regional registries. Nephrol Dial Transplant 16:1120, 2001.
3. Canadian Organ Replacement Registry: C.O.R.R. 2000 Report, Volumes 1 and 2: Dialysis and renal transplantation, Canadian Organ Replacement Register. Ottawa: Canadian Institute for Health Information; 2000.
4. Australia and New Zealand Data Registry: ANZDATA Registry Report 2000, Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia: Author; 2000.
5. C.M.T.S: A randomized clinical trial of cyclosporine in cudaveric renal transplantation. N Engl J Med 309:809, 1983.
6. Keown P, Niese D. f.t.I.N.S. Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal allograft recipients. Kidney Int 54:938, 1998.
7. Keown PA: New immunosuppressive strategies. Curr Opin Nephrol Hypertens 7:659, 1998.
8. Halloran PF: New trends in immunosuppression for renal transplantation. Curr Opin Nephrol Hypertens, 3:575, 1994.
9. Ishikawa Al, et al: Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 68:1318, 1999.
10. Keown PA, Shackleton C.R, Ferguson B.M: The influence of long-term morbidity on health status and rehabilitation following paediatric organ transplantation. Eur J Pediatr 151:S70, 1992.
11. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799, 1998.
12. Steinman TI, et al: Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 71:1189, 2001.
13. Wolfe RA, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725, 1999.
14. Ponticelli C, et al: Risk factors for late kidney allograft failure. Kidney Int 62:1848, 2002.
15. Hariharan S: Long-term kidney transplant survival. Am J Kidney Dis 38(suppl 6):S44, 2001.
16. Meier-Kriesche HU, Kaplan B: Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2:100, 2002.
17. Opelz G, Dohler B: Cyclosporine and long-term kidney graft survival. Transplantation 72:1267, 2001.
18. Kahan BD, et al: Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62:599, 1996.
19. Nashan B, et al: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193, 1997.
20. Lawen JG, et al: Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75:37, 2003.
21. Ponticelli C, et al: A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72:1261, 2001.
22. 22. Nashan B: Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 24:53, 2002.
23. Thervet E, et al: Clinical outcomes during the first 3 months post-transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion (Neoral®). Transplantation 76:903, 2003.
24. Hariharan S, et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605, 2000.
25. Heisel O, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors. Am J Transplant (Submitted) 2003.
26. Evans RW, Manninen DL, Garrison LP: The quality of life of patients with end-stage renal disease. N Eng J Med 312:553, 1985.
27. Churchill DN, et al: Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 10:14, 1987.
28. Simmons RG, Anderson, CR, Abress LK: Quality of life and rehabilitation differences among four end-stage renal disease therapy groups. Scand J Urol Nephrol 131(suppl):7, 1990.
29. Dew MA, et al: Does transplantation produce quality of life benefits? A quantitative analysis of the literature. Transplantation 64:1261, 1997.
30. Laupacis A, et al: A study of the cost utility of renal transplantation. Kidney Int 50:235, 1996.
31. Laupacis A, et al: Disease-specific questionnaire for patients with a renal transplant. Nephron 64:226, 1993.
32. Shield CF, McGrath MM, Gross TF: Assessment of healthrelated quality of life in kidney transplant patients receiving tacrolimus (FK5006)-based versus cyclosporine-based immunosuppression. Transplantation 64:1738, 1997.
33. Kreis H, et al: Quality of life assessment in strolimus-treated renal transplant patients after cyclosporine elimination. In European Society of Dialysis and Transplantation. Vienna, 2001.
34. Wlodarezyk Z, et al: Vocational rehabilitation following kidney transplantation. Ann Transplant 4:40, 1999.
35. Evans RW, Kitzmann DJ: An economic analysis of renal transplantation. Surg Clin North Am 78:149, 1998.
36. Keown PA, et al: Economic analysis of sandimmune neoral in Canadian stable renal transplant patients. Transplant Proc 27:1845, 1995.
37. Sullivan SD, et al: The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. J Am Soc Nephrol 8:159, 1997.
38. Keown PA, et al: An economic analysis of mycophenolate mofetil for preventing acute rejection in renal transplantation: a Canadian perspective. Pharmacoeconomics, 2003 (submitted).
39. Keown PA, et al: An economic model of Simulect in renal transplantation. Transplantation 71:1573, 2001.
40. Keown PA, et al: An economic model of two-hour post-dose cyclosporine monitoring in renal transplantation. Pharmacoeconomics, (submitted).
41. Sharples LD, et al: A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation 62: 615, 1996.